Treatment of anaplastic lymphoma kinase-positive lung adenocarcinoma with pemetrexed and carboplatin after crizotinib failure and significant liver dysfunction; a case report

Oranus Mohammadi, Kayla Haines, Mohammad Jahanzeb

Research output: Contribution to journalArticlepeer-review

Abstract

Tyrosine kinase inhibitors are the first-line treatment for Anaplastic Lymphoma Kinase-positive lung adenocarcinomas. However, chemotherapy is still an option in patients who are unresponsive or intolerant of tyrosine kinase inhibitors. There is a high likelihood of brain metastasis in patient with lung adenocarcinomas with Anaplastic Lymphoma Kinase rearrangement. Surveillance brain imaging may have a role in clinical follow up. Brigatinib and lorlatinib are two tyrosine kinase inhibitors with excellent intracranial penetrance.

Original languageEnglish (US)
Article number100291
JournalCancer Treatment and Research Communications
Volume26
DOIs
StatePublished - Jan 2021
Externally publishedYes

Keywords

  • Brigatinib
  • Genomic Profiling
  • Immunotherapy
  • Lorlatinib
  • Non-small cell lung cancer

ASJC Scopus subject areas

  • Oncology
  • Cancer Research

Fingerprint Dive into the research topics of 'Treatment of anaplastic lymphoma kinase-positive lung adenocarcinoma with pemetrexed and carboplatin after crizotinib failure and significant liver dysfunction; a case report'. Together they form a unique fingerprint.

Cite this